Oxford Biomedica signs up for 3 more years of making AstraZeneca COVID shots⁠—on an 'as needed basis'

There was a time—not so long ago—when COVID-19 vaccine manufacturers couldn’t produce doses fast enough. But that was then, and this is now: Friday, when Oxford Biomedica revealed an extension of its contract with AstraZeneca through 2025, the deal was to make shots on an “as needed basis,” the company said. This comes just nine months after Oxford announced a 50 million pound sterling ($68 million) investment from the over-strapped Serum Institute of India to increase its ability to manufacture COVID vaccines for AZ at its Oxbox facility.